Luther King Capital Management (LKCM)’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$60.2M Sell
2,498,042
-100,898
-4% -$2.64M 0.25% 81
2026
Q1
$73M Buy
2,598,940
+10,298
+0.4% +$274K 0.32% 75
2025
Q4
$64.5M Sell
2,588,642
-117,825
-4% -$2.97M 0.26% 80
2025
Q3
$69M Sell
2,706,467
-14,810
-0.5% -$366K 0.28% 77
2025
Q2
$66M Buy
2,721,277
+22,345
+0.8% +$521K 0.29% 80
2025
Q1
$68.4M Buy
2,698,932
+163,847
+6% +$4.29M 0.32% 77
2024
Q4
$67.3M Buy
2,535,085
+34,070
+1% +$924K 0.29% 78
2024
Q3
$72.4M Buy
2,501,015
+143,833
+6% +$4.2M 0.31% 75
2024
Q2
$66M Buy
2,357,182
+207,837
+10% +$5.72M 0.3% 74
2024
Q1
$59.6M Buy
2,149,345
+138,329
+7% +$3.84M 0.27% 84
2023
Q4
$57.9M Buy
2,011,016
+11,863
+0.6% +$359K 0.28% 80
2023
Q3
$66.3M Sell
1,999,153
-78,140
-4% -$2.76M 0.34% 70
2023
Q2
$76.2M Sell
2,077,293
-107,595
-5% -$4.19M 0.38% 71
2023
Q1
$89.1M Sell
2,184,888
-92,248
-4% -$3.98M 0.47% 66
2022
Q4
$117M Sell
2,277,136
-2,617
-0.1% -$125K 0.64% 53
2022
Q3
$99.8M Sell
2,279,753
-3,846
-0.2% -$187K 0.6% 53
2022
Q2
$120M Sell
2,283,599
-6,795
-0.3% -$346K 0.67% 45
2022
Q1
$119M Buy
2,290,394
+10,339
+0.5% +$536K 0.58% 56
2021
Q4
$135M Buy
2,280,055
+22,664
+1% +$1.12M 0.61% 49
2021
Q3
$97.1M Sell
2,257,391
-133,942
-6% -$5.93M 0.48% 68
2021
Q2
$93.6M Sell
2,391,333
-55,044
-2% -$2.14M 0.46% 71
2021
Q1
$88.6M Sell
2,446,377
-60,669
-2% -$2.15M 0.48% 67
2020
Q4
$92.3M Sell
2,507,046
-200,152
-7% -$7.34M 0.52% 59
2020
Q3
$94.3M Buy
2,707,198
+19,967
+0.7% +$700K 0.6% 52
2020
Q2
$83.4M Sell
2,687,231
-461,921
-15% -$15.7M 0.58% 53
2020
Q1
$97.5M Buy
3,149,152
+86,505
+3% +$2.95M 0.84% 38
2019
Q4
$114M Sell
3,062,647
-1,542
-0.1% -$54.9K 0.76% 44
2019
Q3
$104M Buy
3,064,189
+5,131
+0.2% +$187K 0.76% 47
2019
Q2
$126M Sell
3,059,058
-26,014
-0.8% -$1.03M 0.92% 40
2019
Q1
$124M Sell
3,085,072
-37,518
-1% -$1.5M 0.95% 41
2018
Q4
$129M Sell
3,122,590
-16,460
-0.5% -$683K 1.15% 32
2018
Q3
$131M Sell
3,139,050
-97,402
-3% -$3.75M 0.99% 34
2018
Q2
$111M Sell
3,236,452
-157,529
-5% -$5.38M 0.91% 41
2018
Q1
$114M Sell
3,393,981
-389
-0% -$13.4K 0.96% 37
2017
Q4
$117M Buy
3,394,370
+455,827
+16% +$15.5M 0.95% 36
2017
Q3
$99.5M Sell
2,938,543
-71,544
-2% -$2.3M 0.87% 46
2017
Q2
$95.9M Sell
3,010,087
-59,283
-2% -$1.87M 0.87% 44
2017
Q1
$99.6M Sell
3,069,370
-96,805
-3% -$3.05M 0.92% 42
2016
Q4
$97.6M Buy
3,166,175
+8,650
+0.3% +$264K 0.93% 41
2016
Q3
$101M Buy
3,157,525
+8,542
+0.3% +$286K 0.99% 35
2016
Q2
$105M Sell
3,148,983
-1,334
-0% -$42.6K 1.03% 33
2016
Q1
$88.6M Sell
3,150,317
-7,403
-0.2% -$211K 0.88% 42
2015
Q4
$96.7M Sell
3,157,720
-61,276
-2% -$1.93M 0.91% 36
2015
Q3
$95.9M Buy
3,218,996
+57,774
+2% +$1.85M 0.93% 35
2015
Q2
$101M Sell
3,161,222
-218,664
-6% -$7.13M 0.87% 40
2015
Q1
$112M Buy
3,379,886
+42,139
+1% +$1.34M 0.93% 37
2014
Q4
$98.6M Sell
3,337,747
-4,412
-0.1% -$127K 0.8% 42
2014
Q3
$93.8M Sell
3,342,159
-87,460
-3% -$2.45M 0.77% 43
2014
Q2
$96.6M Buy
3,429,619
+86,672
+3% +$2.47M 0.76% 45
2014
Q1
$102M Buy
3,342,947
+21,958
+0.7% +$655K 0.83% 34
2013
Q4
$96.5M Sell
3,320,989
-13,814
-0.4% -$402K 0.78% 37
2013
Q3
$90.9M Buy
3,334,803
+60,402
+2% +$1.64M 0.78% 34
2013
Q2
$87M Buy
+3,274,401
New +$90.5M 0.81% 32

Other funds holding PFE

Luther King Capital Management (LKCM)'s PFE Position: Q2 2026 in Review

Luther King Capital Management (LKCM) reduced its Pfizer (PFE) stake by 3.9% in Q2 2026, selling an estimated $2.64M and leaving 2,498,042 shares worth $60.2M. The position accounts for 0.25% of the portfolio, ranked #81.

Luther King Capital Management (LKCM) first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $135M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Luther King Capital Management (LKCM) held 2,498,042 shares of Pfizer worth $60.2M as of Q2 2026.
  • Luther King Capital Management (LKCM) sold 100,898 Pfizer shares in Q2 2026, an estimated $2.64M.
  • Pfizer made up 0.25% of Luther King Capital Management (LKCM)'s portfolio in Q2 2026, its #81 holding.
  • Luther King Capital Management (LKCM) first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Luther King Capital Management (LKCM)'s Pfizer position peaked at $135M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Luther King Capital Management (LKCM)'s 13F filing for Q2 2026, filed 10 Aug 2026.